Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Well informed: How to Take full advantage of Your Gadgets - 2Ryan Gosling responds to Deidre Hall's invitation to visit the 'Days of Our Lives' set: 'This is a very enthusiastic yes'
- 3How HIV/AIDS got its name − the words Americans used for the crisis were steeped in science, stigma and religious language
- 4Paraplegic engineer becomes the first wheelchair user to blast into space
- 5A Lone Wolf Outsmarted Hunters in the Black Forest and Then Vanished
- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
- Instructions to Discuss Successfully with Your Auto Collision Lawyer
- Wegovy maker Novo sharpens consumer focus with board role for Mars CEO
- IDF destroys Hamas shaft in northern Gaza with loaded 'ready to fire' rocket aimed at Sderot
- Zelensky warns of imminent massive Russian attack on Ukraine
- Cruising Solo All over the Planet: An Excursion of Self-Disclosure
- 7 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
- FDA proposes use of sunscreen ingredient popular in other countries
